{"id":"W4385476260","doi":"10.1182/bloodadvances.2023010334","title":"Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Merck Sharp and Dohme; Celgene; MorphoSys; Innovent Biologics; Regeneron Pharmaceuticals; Seagen; Pfizer; Hexal AG; Genentech; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Cohort; Internal medicine; Refractory (planetary science); Brentuximab vedotin; Lymphoma; Confidence interval; Progression-free survival; Gastroenterology; Surgery; Oncology; Overall survival; Hodgkin lymphoma; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002801014,0.0002836043,0.0004969005,0.00005736264,0.0002868674,0.00005169914,0.0001924597,0.00008266349,0.00008177861],"category_scores_gemma":[0.0002162621,0.0001792883,0.0002234101,0.000285978,0.0001088291,0.0001621846,0.00009507031,0.00008603551,0.0001749631],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008665807,"about_ca_system_score_gemma":0.0001326087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001625561,"about_ca_topic_score_gemma":0.0001957099,"domain_scores_codex":[0.9980653,0.00009121026,0.0003572549,0.0005461855,0.0004594274,0.000480656],"domain_scores_gemma":[0.998311,0.0008062253,0.0001300662,0.000515956,0.00007648097,0.0001602957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005087939,0.05766614,0.6419311,0.0001371064,0.003465831,0.001547303,0.002929819,0.00001732172,0.002774085,0.001147873,0.02609672,0.2571988],"study_design_scores_gemma":[0.1187291,0.009027906,0.6220024,0.0001700084,0.00218517,0.00002672108,0.006707868,0.0001724974,0.005639198,0.0006318029,0.234139,0.0005684205],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926845,0.002520661,0.00001143348,0.001300877,0.000779835,0.001364004,0.0003166193,0.0002453429,0.0007767392],"genre_scores_gemma":[0.9962618,0.000548034,0.000304032,0.0001560033,0.0008280373,0.000565951,0.0002310957,0.00005047798,0.001054615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2566304,"threshold_uncertainty_score":0.7311166,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02890083118372735,"score_gpt":0.3261303128704693,"score_spread":0.297229481686742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}